The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Longterm Safety of Patients Receiving Rituximab in Rheumatoid Arthritis Clinical Trials
Open accessAbstract
Objective.: To evaluate the longterm safety of rituximab in clinical trials in patients with rheumatoid arthritis (RA). Methods.: Pooled analysis of safety data, including adverse events (AE) and infections, from patients treated with rituximab in combination with methotrexate in a global clinical trial program. Results.: A total of 2578 patients with RA received at least 1 course of rituximab. Safety analyses were based on 5013 patient-years of rituximab exposure. The most frequent AE was infusion-related reactions (25% of patients during the first infusion of Course 1). Less than 1% of infusion-related reactions were considered serious. Rates of AE and serious AE (SAE; 17.85 events/100 patient-yrs, 95% CI 16.72, 19.06) were stable following each course. The overall serious infection rate was 4.31/100 patient-years (95% CI 3.77, 4.92). Infections and serious infections over time remained stable across 5 courses at 4–6 events/100 patient-years. Compared with other patients with RA and with the general US population, there was no increased risk of malignancy. Conclusion.: In this longterm safety update in RA clinical trial patients, rituximab remained well tolerated over multiple courses. SAE and infections remained stable over time and by treatment course.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis
Edwards, J. C. W., Szczepański, L., Szechiński, J., Filipowicz-Sosnowska, A., Emery, P., Close, D. R., Stevens, R. M., & Shaw, T. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032534 · Cited by 2,623
Self-citationBongartz, T., Sutton, A. J., Sweeting, M. J., Buchan, I., Matteson, E. L., & Montori, V. (2006) · JAMA · doi:10.1001/jama.295.19.2275 · Cited by 2,468
B-cell depletion with rituximab in relapsing-remitting multiple sclerosis
Hauser, S. L., Waubant, E., Arnold, D. L., Vollmer, T., Antel, J., Fox, R. J., Bar-Or, A., Panzara, M., Sarkar, N., Agarwal, S., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0706383 · Cited by 2,439
Maloney, D. G., Grillo-López, A. J., White, C. A., Bodkin, D., Schilder, R. J., Neidhart, J. A., Janakiraman, N., Foon, K. A., Liles, T.-M., Dallaire, B. K., et al. (1997) · Blood · doi:10.1182/blood.v90.6.2188 · Cited by 1,733
Cohen, S. B., Emery, P., Greenwald, M. W., Dougados, M., Furie, R. A., Genovese, M. C., Keystone, E. C., Loveless, J. E., Burmester, G., Cravets, M. W., et al. (2006) · Arthritis & Rheumatism · doi:10.1002/art.22025 · Cited by 1,638
Self-citationEmery, P., Fleischmann, R., Filipowicz‐Sosnowska, A., Schechtman, J., Szczepanski, L., Kavanaugh, A., Racewicz, A. J., van Vollenhoven, R. F., Li, N. F., Agarwal, S., et al. (2006) · Arthritis & Rheumatism · doi:10.1002/art.21778 · Cited by 1,060
Self-citationBaecklund, E., Iliadou, A., Askling, J., Ekbom, A., Backlin, C., Granath, F., Catrina, A. I., Rosenquist, R., Feltelius, N., Sundström, C., et al. (2006) · Arthritis & Rheumatism · doi:10.1002/art.21675 · Cited by 890
Dixon, W. G., Watson, K. D., Lunt, M., Hyrich, K. L., Silman, A. J., & Symmons, D. P. M. (2007) · Arthritis & Rheumatism · doi:10.1002/art.22809 · Cited by 562
Rituximab in relapsing‐remitting multiple sclerosis: A 72‐week, open‐label, phase I trial
Bar‐Or, A., Calabresi, P. A. J., Arnold, D., Markowitz, C., Shafer, S., Kasper, L. H., Waubant, E., Gazda, S., Fox, R. J., Panzara, M., et al. (2008) · Annals of Neurology · doi:10.1002/ana.21363 · Cited by 527
Practice parameter for the diagnosis and management of primary immunodeficiency
Bonilla, F. A., Bernstein, I. L., Khan, D. A., Ballas, Z. K., Chinen, J., Frank, M. M., Kobrynski, L. J., Levinson, A. I., Mazer, B., Nelson, R. P., et al. (2005) · Annals of Allergy, Asthma & Immunology · doi:10.1016/s1081-1206(10)61142-8 · Cited by 521
Cited by
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2010
Furst, D. E., Keystone, E. C., Braun, J., Breedveld, F. C., Burmester, G. R., De Benedetti, F., Dörner, T., Emery, P., Fleischmann, R., Gibofsky, A., et al. (2011) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2010.146852 · Cited by 687
Self-citationRituximab for the Treatment of IgG4-Related Disease: Lessons From 10 Consecutive Patients
Khosroshahi, A., Carruthers, M. N., Deshpande, V., Unizony, S., Bloch, D. B., & Stone, J. H. (2012) · Medicine · doi:10.1097/md.0b013e3182431ef6 · Cited by 489
Bingham, C. O., Looney, R. J., Deodhar, A., Halsey, N., Greenwald, M., Codding, C., Trzaskoma, B., Martin, F., Agarwal, S., & Kelman, A. (2010) · Arthritis & Rheumatism · doi:10.1002/art.25034 · Cited by 459
Self-citationBarmettler, S., Ong, M.-S., Farmer, J. R., Choi, H., & Walter, J. (2018) · JAMA Network Open · doi:10.1001/jamanetworkopen.2018.4169 · Cited by 357
Rituximab for Non-Infectious Uveitis and Scleritis
Ng, C. C., Sy, A., & Cunningham, E. T. (2021) · Journal of Ophthalmic Inflammation and Infection · doi:10.1186/s12348-021-00252-4 · Cited by 40
Metadata
- Authors
- van VOLLENHOVEN, R. F., EMERY, P., BINGHAM, C. O., KEYSTONE, E. C., FLEISCHMANN, R., FURST, D. E., MACEY, K., SWEETSER, M., KELMAN, A., & RAO, R.
- Venue
- The Journal of Rheumatology
- Publisher
- The Journal of Rheumatology
- Published
- 2010-01-28
- Volume
- 37
- Issue
- 3
- Pages
- 558-567
- ISSN
- 0315-162X (ISSN-L)
- 1499-2752
- OpenAlex
- W2106997293
- Cited by
- 287
- References
- 33
- FWCI
- 24.49
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Longterm Safety of Patients Receiving Rituximab in Rheumatoid Arthritis Clinical Trials. https://app.cochat.ai/papers/10.3899/jrheum.090856
- The paper
- van VOLLENHOVEN, R. F., EMERY, P., BINGHAM, C. O., KEYSTONE, E. C., FLEISCHMANN, R., FURST, D. E., MACEY, K., SWEETSER, M., KELMAN, A., & RAO, R. (2010). Longterm Safety of Patients Receiving Rituximab in Rheumatoid Arthritis Clinical Trials. The Journal of Rheumatology. https://doi.org/10.3899/jrheum.090856
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
